BioLine Rx Ltd

NAS:BLRXHealthcarenasdaq_composite

$2.01−1.95%At closeAt close · Sat 17 Oct · ≈ AED 7.38 · Market cap — · Next earnings Wed 18 Nov · Extended $2.06 +2.49%

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	—	—	—	23.1%	68.0%	36.2%	—	—
Operating margin	—	—	—	−1,035.3%	−70.5%	−871.8%	−871.8%	+0.0 pts
Net margin	—	—	—	−1,262.8%	−31.9%	−99.6%	−99.6%	+0.0 pts
EBITDA margin	—	—	—	−1,189.3%	13.5%	−18.9%	—	—
Return on equity	−136.3%	−39.7%	−49.1%	−458.4%	−68.5%	−6.5%	−5.1%	+1.4 pts
Return on assets	−63.5%	−33.2%	−32.7%	−94.8%	−23.7%	−2.9%	−2.9%	+0.0 pts
Return on capital employed	−62.6%	−34.6%	−44.4%	−235.1%	−86.8%	−36.0%	—	—
Debt / equity	0.3×	0.1×	0.2×	0.9×	1.1×	0.6×	0.4×	−22.1%
Debt / assets	16.2%	5.7%	16.1%	18.1%	38.7%	24.8%	—	—
Interest coverage	−15.6×	−25.2×	−13.5×	−22.9×	−2.2×	−8.0×	—	—
Current ratio	2.2×	5.9×	4.9×	1.1×	1.8×	2.0×	2.0×	+0.0%
Quick ratio	2.2×	5.9×	4.9×	1.1×	1.6×	1.8×	—	—
Cash ratio	1.6×	1.3×	1.0×	0.1×	0.7×	0.3×	0.3×	+0.0%
Asset turnover	0.0×	0.0×	0.0×	0.1×	0.7×	0.0×	—	—
Inventory turnover	—	0.0×	0.0×	1.9×	2.9×	0.4×	—	—
Receivables turnover	0.0×	0.0×	0.0×	6.8×	7.5×	2.6×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.